Abstract
Botulinum neurotoxins (BoNTs) are used in the treatment of many neurological disorders. The primary structure of BoNTs shows a high degree of homology with the tetanus neurotoxin, the toxoid of which is used as a vaccine. Because of the potential cross-reactivity between these toxins, we investigated the effects of Botulinum neurotoxin A (BoNT/A) and tetanus toxoid on peripheral blood mononuclear cells (PBMC) and the corresponding serum antibody levels, in twenty patients who had been treated with BoNT/A. We observed very low PBMC immunostimulation by BoNT/A at the tested dose (15 units/ml), as demonstrated by the low lymphocyte proliferation, and the absence of detectable antibodies cross-reacting with tetanus. However, exposure of PBMC from tetanus-sensitized patients to both neurotoxins showed that BoNT/A exerted a co stimulatory effect on tetanus-stimulated cells. Interestingly, in flow cytometry analysis, BoNT/A seemed to also alter the ratio of naïve (CD45RA) : memory/effector (CD45RO) T lymphocyte subsets, in favour of CD45RO. These preliminary data give a new insight on the potential immune crossreactivity between the two antigens. In view of the wide use of both neurotoxins, these immunotoxic effects merit a more detailed investigation.
Keywords: Antibody assay, botulinum neurotoxin (A), PBMC proliferation, tetanus neurotoxin, BoNT/A, anti-tetanus antibody levels, Pharmingen, Clostridium botulinum, neurotoxins, immunostimulation.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Evaluation of Specific Immune Responses to BoNT/A and Tetanus Toxoid in Patients Undergoing Treatment for Neurologic Disorders
Volume: 12 Issue: 3
Author(s): Zaharenia Vlata, Aristidis Tsatsakis, Minas Tzagournissakis and Elias Krambovitis
Affiliation:
Keywords: Antibody assay, botulinum neurotoxin (A), PBMC proliferation, tetanus neurotoxin, BoNT/A, anti-tetanus antibody levels, Pharmingen, Clostridium botulinum, neurotoxins, immunostimulation.
Abstract: Botulinum neurotoxins (BoNTs) are used in the treatment of many neurological disorders. The primary structure of BoNTs shows a high degree of homology with the tetanus neurotoxin, the toxoid of which is used as a vaccine. Because of the potential cross-reactivity between these toxins, we investigated the effects of Botulinum neurotoxin A (BoNT/A) and tetanus toxoid on peripheral blood mononuclear cells (PBMC) and the corresponding serum antibody levels, in twenty patients who had been treated with BoNT/A. We observed very low PBMC immunostimulation by BoNT/A at the tested dose (15 units/ml), as demonstrated by the low lymphocyte proliferation, and the absence of detectable antibodies cross-reacting with tetanus. However, exposure of PBMC from tetanus-sensitized patients to both neurotoxins showed that BoNT/A exerted a co stimulatory effect on tetanus-stimulated cells. Interestingly, in flow cytometry analysis, BoNT/A seemed to also alter the ratio of naïve (CD45RA) : memory/effector (CD45RO) T lymphocyte subsets, in favour of CD45RO. These preliminary data give a new insight on the potential immune crossreactivity between the two antigens. In view of the wide use of both neurotoxins, these immunotoxic effects merit a more detailed investigation.
Export Options
About this article
Cite this article as:
Vlata Zaharenia, Tsatsakis Aristidis, Tzagournissakis Minas and Krambovitis Elias, Evaluation of Specific Immune Responses to BoNT/A and Tetanus Toxoid in Patients Undergoing Treatment for Neurologic Disorders, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/187153012802002893
DOI https://dx.doi.org/10.2174/187153012802002893 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Extracorporeal Detoxification by MARS Dialysis in Patients with Liver Failure
Current Medicinal Chemistry Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Current Pharmaceutical Design Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study
Current Alzheimer Research Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry The Impact of Computer Science in Molecular Medicine: Enabling High- Throughput Research
Current Topics in Medicinal Chemistry Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Human Apolipoprotein C-III – A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins
Cardiovascular & Hematological Disorders-Drug Targets Obesity and Body Fat Distribution as Predictors for Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Zinc and Type 2 Diabetes Mellitus with Periodontitis- A Systematic Review
Current Diabetes Reviews Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry Glucagon-like Peptides, the Central Nervous System, and the Regulation of Energy Homeostasis
Current Medicinal Chemistry - Central Nervous System Agents Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Patent Annotations
Recent Patents on Drug Delivery & Formulation Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Current Drug Targets Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued)